

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Yao-Tseng Chen, et al.

Serial No. : 08/560,024

Filed : November 17, 1996

For : MONOCLONAL ANTIBODIES WHICH BIND

TO TUMOR REJECTION ANTIGEN PRE-CURSOR MAGE-1, RECOMBINANT MAGE-1,

AND MAGE-1 DERIVED IMMUNOGENIC

PEPTIDES

\_\_\_\_\_

February 14, 1996

Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231

## LETTER

Sir:

In accordance with the Notice of February 5, 1996 (copy attached), applicants do not understand the requirement for sequence diskette. This application is a divisional of an application which contained a sequence diskette. Applicants filed a paper in accordance with 37 C.F.R. §1.821e, MPEP 2422.05, asking that the sequence information from the patent case be used.

Copies of the executed Declaration/Power of Attorney forms from the parent case are attached.

A check for \$65.00, for a Small Entity, is also attached.

In view of this, it is believed that the Notice of February 5 should be withdrawn.

Respectfully submitted,


FELFE & LYNCH

Norman D. Hanson

Reg. No. 30,946

805 Third Avenue New York, New York 10022 (212) 688-9200 FEB 84

For Patentin software help, call (703) 308-6856



## NOTICE 1806 ONE LY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLES TIPE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

|                         | 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.   |
|-------------------------|---|
|                         | 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). —  |
| Ø                       | 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).  |
|                         | 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing." |
| _                       |   |
|                         | 5. The computer readable form that has been filed with this application has been found to be damaged and/or   |
|                         | unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).  |
|                         | 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).   |
|                         |   |
|                         | .7. Other: ————————————————————————————————————   |
|                         | Y .   |
| Applicant must provide: |   |
|                         |   |
|                         | An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"  |
|                         | An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification   |
| X                       | A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)  |
| For                     | questions regarding compliance with these requirements, please contact:   |
|                         | Rules Interpretation, call (703) 308-1123 CRF submission help, call (703) 308-4212  |

Please return a copy of this notice with your response.